Dong-A Pharm signs agreement with Novartis Korea for exclusive sales right for Exelon

Published: 2004-01-09 07:00:00

Updated: 2004-01-09 07:00:00

Dong-A Pharm said on January 6 that it signed a letter of intent with Novartis Korea, a Korean unit of Switzerland-based multinational pharmaceutical firm, for exclusive sales in Korea of Exelon (rivastigmine) which have been indicated for the treatment of Alzheimer's Disease (AD). The drug was initially introduced by Novartis Korea in June 1999.

Dong-A officials said that Exelon will be lau...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.